Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant atezolizumab before radical surgery for urothelial cancer
ISRCTN22771691Phase 2Active, not recruiting
- Sponsor
- Queen Mary University of London
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of atezolizumab in transitional cell carcinoma (TCC), upper tract urothelial carcinoma (UTUC) and bladder cancer, sponsored by Queen Mary University of London. Primary endpoints: Pathological complete response rate and Change in tumor immune parameters. Started Jun 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)upper tract urothelial carcinoma (UTUC)bladder cancer
Beyond the preview
Go deeper on ISRCTN22771691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN22771691.